



| Revenue | $100 - $500 million See Exact Annual Revenue |
|---|---|
| Employees | 100 - 500Exact Company Size |
| Primary Industry | 5417 Scientific Research & Development Services |
| Additional NAICS Codes | 325412 Pharmaceutical Preparation Manufacturing 44611 Pharmacies & Drug Stores |
| Address | 1375 W Fulton St Ste 1300 Chicago, IL 60607 |
| Xeris Pharmaceuticals | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
|---|---|---|---|
| 2025 | $100 - $500 million Details in Premium Report | ||
| 2024 | |||
| 2023 | |||
| 2021 | |||
| 2020 | |||
| 2019 | |||
|
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
| Xeris Pharmaceuticals P&L | $ Millions |
|---|---|
| Revenue (Sales) | ![]() |
| Cost of Goods Sold | |
| Gross Profit | |
Operating Expenses | |
| Advertising | |
| Salaries and wages | |
| Other Operating Expenses | |
| Total Operating Expenses | |
| Operating Income | |
| EBITDA | |
| EBIT (Earnings Before Interest and Taxes) | |
| Net Profit | |
| Date | Investors | Percent Raised | Target Size |
|---|---|---|---|
| May 22, 2017 | 22 | 67% | $45 MM |
| Complete list of funding rounds and total amounts in the Company Report | |||
| Trademark | Date |
|---|---|
| GVOKE VIALDX pharmaceutical preparations for in vivo diagnostic use; pharmaceutical preparations for diagnostic radiology use | 09/01/2023 |
| MYGLUCA HYPOPEN Pharmaceutical products for the treatment of diabetes and metabolic diseases; medical apparatus, namely, a drug delivery device prefilled with pharmaceutical products for the treatment of diabetes and metabolic diseases; pre-filled syringes and vials containing pharmaceutical preparations for the treatment of diabetes and metabolic diseases | 06/22/2018 |
| MYGLUCA Pharmaceutical products for the treatment of diabetes and metabolic diseases; medical apparatus, namely, a drug delivery device prefilled with pharmaceutical products for the treatment of diabetes and metabolic diseases; pre-filled syringes and vials containing pharmaceutical preparations for the treatment of diabetes and metabolic diseases | 06/22/2018 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| LEIDOS | Denver, CO | 100 |
| NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA | Albuquerque, NM | 30 |
| INC RESEARCH | Raleigh, NC | 27 |
| RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK | Albany, NY | 17 |
| FLUOR MARINE PROPULSION | West Mifflin, PA | 15 |
| SYNEOS HEALTH | Raleigh, NC | 13 |
| ILLUMINA | San Diego, CA | 12 |
| UT-BATTELLE | Oak Ridge, TN | 11 |
| PRA HOLDINGS | Raleigh, NC | 11 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| FERMI RESEARCH ALLIANCE | Chicago, IL | 100 |
| PHARMACANN | Chicago, IL | 33 |
| XERIS PHARMACEUTICALS | Chicago, IL | 20 |
| HEALTH UTILITY NETWORK | Chicago, IL | 13 |
| CHAPIN HALL CENTER FOR CHILDREN | Chicago, IL | 9 |
| IIT RESEARCH INSTITUTE | Chicago, IL | 6 |
| Company | Revenue ($ MM) |
|---|---|
![]() | |